Bluejay Diagnostics ends agreement with DLA, CFO departs
- ByInvesting.com
- •
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a near-patient testing system for triage and monitoring of disease progression. The Company's Symphony platform is a technology platform that provides measurements of key diagnostic biomarkers found in whole blood. The Symphony analyzer orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The Company's first product candidate, an IL-6 test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices (IVDs) market, including sepsis, cardio-metabolic diseases, cancer, and other diseases that require rapid tests.